109 related articles for article (PubMed ID: 24500882)
41. Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma.
Abramson JS; Irwin KE; Frigault MJ; Dietrich J; McGree B; Jordan JT; Yee AJ; Chen YB; Raje NS; Barnes JA; Davis B
Cancer; 2019 Nov; 125(21):3692-3698. PubMed ID: 31503324
[No Abstract] [Full Text] [Related]
42. Pluripotent stem cell-derived CD19-CAR iT cells effectively eradicate B-cell lymphoma in vivo.
Lv C; Chen S; Hu F; Huang D; Wang T; Du J; Wang J; Wu H
Cell Mol Immunol; 2021 Mar; 18(3):773-775. PubMed ID: 32541834
[No Abstract] [Full Text] [Related]
43. CD4+ T cell-mediated cytotoxicity is associated with MHC class II expression on malignant CD19+ B cells in diffuse large B cell lymphoma.
Zhou Y; Zha J; Lin Z; Fang Z; Zeng H; Zhao J; Luo Y; Li Z; Xu B
Exp Cell Res; 2018 Jan; 362(2):287-292. PubMed ID: 29174982
[TBL] [Abstract][Full Text] [Related]
44. Are all chimeric antigen receptors created equal?
Park JH; Brentjens RJ
J Clin Oncol; 2015 Feb; 33(6):651-3. PubMed ID: 25605860
[No Abstract] [Full Text] [Related]
45. Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.
Serrano LM; Pfeiffer T; Olivares S; Numbenjapon T; Bennitt J; Kim D; Smith D; McNamara G; Al-Kadhimi Z; Rosenthal J; Forman SJ; Jensen MC; Cooper LJ
Blood; 2006 Apr; 107(7):2643-52. PubMed ID: 16352804
[TBL] [Abstract][Full Text] [Related]
46. Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells.
Pinz K; Liu H; Golightly M; Jares A; Lan F; Zieve GW; Hagag N; Schuster M; Firor AE; Jiang X; Ma Y
Leukemia; 2016 Mar; 30(3):701-7. PubMed ID: 26526988
[TBL] [Abstract][Full Text] [Related]
47. Bispecific antibody treatment of murine B cell lymphoma.
De Jonge J; Heirman C; De Veerman M; Van Meirvenne S; Demanet C; Brissinck J; Thielemens K
Cancer Immunol Immunother; 1997; 45(3-4):162-5. PubMed ID: 9435864
[TBL] [Abstract][Full Text] [Related]
48. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.
Pegram HJ; Lee JC; Hayman EG; Imperato GH; Tedder TF; Sadelain M; Brentjens RJ
Blood; 2012 May; 119(18):4133-41. PubMed ID: 22354001
[TBL] [Abstract][Full Text] [Related]
49. CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas.
Baur K; Buser A; Jeker LT; Khanna N; Läubli H; Heim D; Dirks JC; Widmer CC; Volken T; Passweg JR; Holbro A
Bone Marrow Transplant; 2023 Sep; 58(9):1048-1050. PubMed ID: 37330601
[No Abstract] [Full Text] [Related]
50. Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors.
Brody JD; Goldstein MJ; Czerwinski DK; Levy R
Blood; 2009 Jan; 113(1):85-94. PubMed ID: 18812472
[TBL] [Abstract][Full Text] [Related]
51. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.
Yazawa N; Hamaguchi Y; Poe JC; Tedder TF
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15178-83. PubMed ID: 16217038
[TBL] [Abstract][Full Text] [Related]
52. Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy.
Ding ZC; Huang L; Blazar BR; Yagita H; Mellor AL; Munn DH; Zhou G
Blood; 2012 Sep; 120(11):2229-39. PubMed ID: 22859605
[TBL] [Abstract][Full Text] [Related]
53. A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice.
Poe JC; Minard-Colin V; Kountikov EI; Haas KM; Tedder TF
J Immunol; 2012 Sep; 189(5):2318-25. PubMed ID: 22826319
[TBL] [Abstract][Full Text] [Related]
54. [Not Available].
Salles G; Sesques P; Ferrant E; Safar V; Ghesquieres H; Bachy E
Bull Cancer; 2018 Dec; 105 Suppl 2():S168-S177. PubMed ID: 30686355
[TBL] [Abstract][Full Text] [Related]
55. Control of B-cell lymphoma by therapeutic vaccination and acquisition of immune resistance is independent of direct tumour IFN-gamma signalling.
Rearden R; Sah A; Doff B; Kobayashi T; McKee SJ; Leggatt GR; Mattarollo SR
Immunol Cell Biol; 2016 Jul; 94(6):554-62. PubMed ID: 26786233
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide.
Berge G; Eliassen LT; Camilio KA; Bartnes K; Sveinbjørnsson B; Rekdal O
Cancer Immunol Immunother; 2010 Aug; 59(8):1285-94. PubMed ID: 20422410
[TBL] [Abstract][Full Text] [Related]
57. Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma.
Armstrong AC; Dermime S; Mulryan K; Stern PL; Bhattacharyya T; Hawkins RE
J Immunother; 2004; 27(3):227-31. PubMed ID: 15076140
[TBL] [Abstract][Full Text] [Related]
58. Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice.
Gallagher S; Turman S; Yusuf I; Akhgar A; Wu Y; Roskos LK; Herbst R; Wang Y
Int Immunopharmacol; 2016 Jul; 36():205-212. PubMed ID: 27163209
[TBL] [Abstract][Full Text] [Related]
59. Targeting c-MYC with T-cells.
Helm F; Kammertoens T; Lehmann FM; Wilke A; Bruns H; Mautner J; Bornkamm GW; Gerbitz A
PLoS One; 2013; 8(10):e77375. PubMed ID: 24130880
[TBL] [Abstract][Full Text] [Related]
60. CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas.
Fitzgerald KN; Quesada AE; von Keudell G; Raj S; Lewis NE; Dogan A; Salles G; Palomba ML
Leuk Lymphoma; 2022 Mar; 63(3):751-754. PubMed ID: 34949132
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
